Systemic therapy for bladder cancer - a medical oncologist's perspective

Benjamin A Teply, Jenny J. Kim

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Advanced bladder cancer, both muscle-invasive localized disease and metastatic disease, is managed with systemic chemotherapy. Cisplatin-based multi-agent chemotherapy remains the cornerstone for systemic therapy. MVAC (methotrexate-vinblastine-doxorubicin-cisplatin) has been most rigorously studied, both neoadjuvantly and for palliation of metastatic disease. For metastatic disease, cisplatin-gemcitabine (GC) has compared favorably to MVAC due to improved tolerability with similar efficacy. GC has been adopted as standard therapy. Neoadjuvant chemotherapy for muscle-invasive bladder cancer improves survival among those patients eligible to receive cisplatin. Adjuvant chemotherapy is difficult to administer effectively given morbidity of radical cystectomy, and studies have shown mixed results about its benefit. Non-cisplatin regimens have been investigated but remain experimental and reserved for those not candidates for cisplatin in the metastatic setting. While multiple agents have been studied after metastatic disease progression after cisplatin-based therapy, there remain no FDA-approved therapies for the second line. Future trials with anti-VEGF therapy and immunotherapy are actively being investigated. This review examines the systemic therapy available to oncologists with current evidence and future directions.

Original languageEnglish (US)
Pages (from-to)25-35
Number of pages11
JournalJournal of Solid Tumors
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Cisplatin
gemcitabine
Vinblastine
Methotrexate
Drug Therapy
Doxorubicin
Therapeutics
Muscle Neoplasms
Cystectomy
Adjuvant Chemotherapy
Oncologists
Immunotherapy
Vascular Endothelial Growth Factor A
Disease Progression
Morbidity
Muscles
Survival

Keywords

  • Bladder Cancer
  • Chemotherapy
  • Cisplatin
  • Metastatic
  • Neoadjuvant

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Systemic therapy for bladder cancer - a medical oncologist's perspective. / Teply, Benjamin A; Kim, Jenny J.

In: Journal of Solid Tumors, Vol. 4, No. 2, 01.01.2014, p. 25-35.

Research output: Contribution to journalReview article

@article{dd14306285ae4698b1b30cbca759bd56,
title = "Systemic therapy for bladder cancer - a medical oncologist's perspective",
abstract = "Advanced bladder cancer, both muscle-invasive localized disease and metastatic disease, is managed with systemic chemotherapy. Cisplatin-based multi-agent chemotherapy remains the cornerstone for systemic therapy. MVAC (methotrexate-vinblastine-doxorubicin-cisplatin) has been most rigorously studied, both neoadjuvantly and for palliation of metastatic disease. For metastatic disease, cisplatin-gemcitabine (GC) has compared favorably to MVAC due to improved tolerability with similar efficacy. GC has been adopted as standard therapy. Neoadjuvant chemotherapy for muscle-invasive bladder cancer improves survival among those patients eligible to receive cisplatin. Adjuvant chemotherapy is difficult to administer effectively given morbidity of radical cystectomy, and studies have shown mixed results about its benefit. Non-cisplatin regimens have been investigated but remain experimental and reserved for those not candidates for cisplatin in the metastatic setting. While multiple agents have been studied after metastatic disease progression after cisplatin-based therapy, there remain no FDA-approved therapies for the second line. Future trials with anti-VEGF therapy and immunotherapy are actively being investigated. This review examines the systemic therapy available to oncologists with current evidence and future directions.",
keywords = "Bladder Cancer, Chemotherapy, Cisplatin, Metastatic, Neoadjuvant",
author = "Teply, {Benjamin A} and Kim, {Jenny J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.5430/jst.v4n2p25",
language = "English (US)",
volume = "4",
pages = "25--35",
journal = "Journal of Solid Tumors",
issn = "1925-4067",
publisher = "Sciedu Press",
number = "2",

}

TY - JOUR

T1 - Systemic therapy for bladder cancer - a medical oncologist's perspective

AU - Teply, Benjamin A

AU - Kim, Jenny J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Advanced bladder cancer, both muscle-invasive localized disease and metastatic disease, is managed with systemic chemotherapy. Cisplatin-based multi-agent chemotherapy remains the cornerstone for systemic therapy. MVAC (methotrexate-vinblastine-doxorubicin-cisplatin) has been most rigorously studied, both neoadjuvantly and for palliation of metastatic disease. For metastatic disease, cisplatin-gemcitabine (GC) has compared favorably to MVAC due to improved tolerability with similar efficacy. GC has been adopted as standard therapy. Neoadjuvant chemotherapy for muscle-invasive bladder cancer improves survival among those patients eligible to receive cisplatin. Adjuvant chemotherapy is difficult to administer effectively given morbidity of radical cystectomy, and studies have shown mixed results about its benefit. Non-cisplatin regimens have been investigated but remain experimental and reserved for those not candidates for cisplatin in the metastatic setting. While multiple agents have been studied after metastatic disease progression after cisplatin-based therapy, there remain no FDA-approved therapies for the second line. Future trials with anti-VEGF therapy and immunotherapy are actively being investigated. This review examines the systemic therapy available to oncologists with current evidence and future directions.

AB - Advanced bladder cancer, both muscle-invasive localized disease and metastatic disease, is managed with systemic chemotherapy. Cisplatin-based multi-agent chemotherapy remains the cornerstone for systemic therapy. MVAC (methotrexate-vinblastine-doxorubicin-cisplatin) has been most rigorously studied, both neoadjuvantly and for palliation of metastatic disease. For metastatic disease, cisplatin-gemcitabine (GC) has compared favorably to MVAC due to improved tolerability with similar efficacy. GC has been adopted as standard therapy. Neoadjuvant chemotherapy for muscle-invasive bladder cancer improves survival among those patients eligible to receive cisplatin. Adjuvant chemotherapy is difficult to administer effectively given morbidity of radical cystectomy, and studies have shown mixed results about its benefit. Non-cisplatin regimens have been investigated but remain experimental and reserved for those not candidates for cisplatin in the metastatic setting. While multiple agents have been studied after metastatic disease progression after cisplatin-based therapy, there remain no FDA-approved therapies for the second line. Future trials with anti-VEGF therapy and immunotherapy are actively being investigated. This review examines the systemic therapy available to oncologists with current evidence and future directions.

KW - Bladder Cancer

KW - Chemotherapy

KW - Cisplatin

KW - Metastatic

KW - Neoadjuvant

UR - http://www.scopus.com/inward/record.url?scp=84929410921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929410921&partnerID=8YFLogxK

U2 - 10.5430/jst.v4n2p25

DO - 10.5430/jst.v4n2p25

M3 - Review article

VL - 4

SP - 25

EP - 35

JO - Journal of Solid Tumors

JF - Journal of Solid Tumors

SN - 1925-4067

IS - 2

ER -